MedTrace Logo

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

NCT05070403 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-04-01

No results posted yet for this study

Summary

The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.

Conditions

Interventions

DRUG

Afatinib 40 MG

Participants will receive 40 mg Afatinib, once daily.

Sponsors & Collaborators

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Zeynep Eroglu, MD · Moffitt Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2027-02-28
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05070403 on ClinicalTrials.gov